Granules India gets Health Canada nod for drug for Arthritis pain

The product manufactured by Granules is a bioequivalent to the reference listed drug, Tylenol extended release 650 tablets.

59
Medicine Tablet
Picture: Pixabay

Last Updated on September 1, 2021 by The Health Master

Granules India Limited has received marketing approval from Health Canada for acetaminophen extended-release tablets OTC, 650mg for the treatment of arthritis pain.

The product manufactured by Granules is a bioequivalent to the reference listed drug, Tylenol extended release 650 tablets.

Priyanka Chigurupati, executive director of Granules USA, Inc. & Granules Pharmaceuticals, Inc. said, “We received the approval within eight months of filing. This is a step towards global expansion of our core molecules.

The approval of acetaminophen extended-release tablets OTC, 650mg, a complex Bi-layer extended released based formulations, is a good addition to our portfolio. We will be launching the product in the Canada market soon.”

The drug will be manufactured at the Granules manufacturing facility located in Gagillapur, Hyderabad. Granules now have a total of 2 ANDS approvals from Health Canada.

Aurobindo Pharma gets USFDA nod for cancer treatment drug

USFDA approves drug for severe Itching in kidney disease patients

Zydus Cadila gets USFDA nod for Tofacitinib ER Tablets

GSK gets USFDA nod for Jemperli to treat advanced solid Tumours

Lupin gets tentative USFDA nod for Brivaracetam tablets

Zydus Cadila gets USFDA nod for Mesalamine ER capsules

Indian Pharma exports: Oceania a potential region: Pharmexcil

Drug recall: Dr Reddy’s & Zydus Pharma Recall these drugs

DCGI approves 3 FDCs containing Cefixime & Cefadroxil as rational

CDSCO issues procedure for regulation of 19 FDCs out of 294

Novel antibiotic Nafithromycin for respiratory track infection

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner